Mursla Bio

Mursla Bio is a Cambridge-based biotech developing a novel diagnostic platform centered on the isolation and multiomic analysis of organ-specific extracellular vesicles (EVs) from blood. Its lead program, EvoLiver™, targets the critical unmet need for early liver cancer detection in cirrhosis patients and recently received FDA Breakthrough Device Designation. The company's approach combines proprietary EV biology with machine learning to create scalable, blood-based diagnostic assays with potential applications across multiple organ systems and diseases.

Proprietary platform for isolating organ-specific extracellular vesicles (EVs) from blood, followed by multiomic (proteomic, RNA) analysis enhanced by machine learning to develop non-invasive diagnostic tests.

Competes in the liver cancer surveillance space against ultrasound and other blood-based biomarkers like AFP. More broadly, competes with other liquid biopsy companies focusing on circulating tumor DNA (ctDNA) or total EVs, though Mursla's niche is its claimed ability to isolate organ-specific EV populations.